The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Utility of pre- and post-pembrolizumab (Pembro) Vesical Imaging–Reporting and Data System (VIRADS) to predict the pathological response in muscle-invasive urothelial bladder cancer (MIBC): An analysis of the PURE-01 cohort.
 
Giorgio Brembilla
No Relationships to Disclose
 
Giuseppe Basile
No Relationships to Disclose
 
Marco Bandini
No Relationships to Disclose
 
Daniele Raggi
No Relationships to Disclose
 
Laura Marandino
No Relationships to Disclose
 
Tiago Costa de Padua
No Relationships to Disclose
 
Damiano Alfio Patanè
No Relationships to Disclose
 
Emanuele Crupi
No Relationships to Disclose
 
Andrea Del Prete
No Relationships to Disclose
 
Renzo Colombo
No Relationships to Disclose
 
Maurizio Colecchia
No Relationships to Disclose
 
Roberta Lucianò
No Relationships to Disclose
 
Marco Moschini
No Relationships to Disclose
 
Jeffrey S. Ross
Employment - Foundation Medicine
Leadership - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
Consulting or Advisory Role - Celsius Therapeutics; Tango Therapeutics
Research Funding - Foundation Medicine
 
Alberto Briganti
No Relationships to Disclose
 
Francesco Montorsi
No Relationships to Disclose
 
Francesco De Cobelli
No Relationships to Disclose
 
Andrea Necchi
Employment - Bayer (I)
Stock and Other Ownership Interests - Bayer (I)
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Foundation Medicine; Janssen; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; Bayer; Bristol-Myers Squibb; Catalym; Clovis Oncology; GlaxoSmithKline; Incyte; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche; Seattle Genetics/Astellas
Research Funding - AstraZeneca (Inst); Gilead Sciences; Ipsen; Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Sharp & Dohme; Pfizer; Rainier Therapeutics; Roche
Other Relationship - Bayer (I)